• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Key International Thought Leaders Convening to Accelerate Drug Discovery for Neurodegenerative Diseases

Posted on: Monday, 7 January 2008, 15:00 CST

The Alzheimer's Drug Discovery Foundation organized its 2nd annual "Drug Discovery for Neurodegeneration" Conference, scheduled for February 4-5, 2008 at the Park Hyatt Washington DC. The conference brings together international thought leaders to present and discuss basic concepts and new advances in drug discovery as they relate to neurodegenerative disease.

The goal is to accelerate drug discovery for neurodegenerative diseases by informing academic and biotechnology scientists about basic concepts and available resources. "This conference is particularly timely and important," said conference Chair Howard Fillit, MD, Executive Director of the Alzheimer's Drug Discovery Foundation. "Advances in basic neuroscience research have created numerous opportunities for new therapeutics for neurodegenerative disease. While many academic and industry scientists are increasingly involved in discovering innovative therapeutics for neurodegenerative diseases, they need better perspective, specific knowledge and more access to resources to add value to their drug discovery efforts. We are proud to bring this information to the international community of scientists who are committed to accelerating drug discovery for neurodegeneration."

Speakers and chairs will present lectures and case studies on CNS Target Identification & Validation, Lead Identification & Optimization, Lead Discovery, Pre-Clinical Proof-of-Concept & Development, Resources and Services for Advancing Drug Discovery, and Disease Specific Case Studies in Drug Discovery for Neurodegenerative Disease. The conference will particularly focus on Alzheimer's disease, Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis. A detailed conference agenda and registration forms are available online at www.alzdiscovery.org.

The conference is supported in part by conference grant U13-AG031125 from the National Institute on Aging and the National Institute for Neurological Disorders and Stroke; additional sponsors include CoMentis, Pfizer and Boehringer-Ingelheim. The conference is CME accredited and will also be available via webcast.

Co-sponsorship opportunities are still available. For more information, call Filomena Machleder at 212-901-8004. Questions regarding registration, contact World Events Forum at 773-784-8134.

FOR MORE INFORMATION & TO REGISTER, VISIT: www.alzdiscovery.org

TO REQUEST A PRESS PASS OR BE A MEDIA PARTNER, PLEASE CONTACT: Conference Secretariat: meetings@worldeventsforum.com

ATTENTION CALENDAR EDITORS: Please list this meeting in your publication's calendar.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease (AD), related dementias and cognitive aging through venture philanthropy. To date, ADDF and ISOA have awarded $28.7 million for 195 research programs and conferences worldwide. For more information, visit www.AlzDiscovery.org.

 ADDF Contact: Filomena Machleder Partnership Relations Manager +1 (212) 901-8004 FMachleder@alzdiscovery.org

SOURCE: Alzheimer's Drug Discovery Foundation

Source: MARKET WIRE

More News in this Category